Drug Lists by Risk Groups
Drugs that Prolong the QT Interval and/or Induce Torsades de Pointes
Drug-induced torsades de pointes (TdP) is a specific type of ventricular arrhythmia that is associated with prolongation of the QT interval on the electrocardiogram. It is a well-understood form of drug toxicity. Because the the evidence for risk of TdP is often imperfect, we have divided the drugs into four groups based on our analysis of the evidence:
- Risk of TdP: Substantial evidence supports the conclusion that these drugs prolong QT intervals and have a risk of TdP when used as directed in labeling.
- Possible risk of TdP: Substantial evidence supports the conclusion that these drugs can cause QT prolongation but there is insufficient evidence that the drugs, when used as directed in labeling, have a risk of causing TdP.
- Conditional risk of TdP: Substantial evidence supports the conclusion that these drugs prolong QT and have a risk of developing TdP but only under certain known conditions.
- Drugs to be avoided, if possible, for patients with congenital LQTS.
(clicking this link will take you to the brugadadrugs.org website)
Notes about the Lists:
Drugs not listed here may have an, as yet, undetected potential to prolong the QT interval or induce torsades de pointes. Not all drugs have been adequately tested for this potential. Therefore, the absence of a drug from these lists should not be considered an indication that they are free of risk of QT prolongation or torsades de pointes.
Drugs are listed with up to 2 common brand names. Drugs often have more than one brand name. For these lists, only the 2 most common brand names are included.
The lists are formatted to be viewed online or for printing.
SEARCH PUBMED TO SEE LITERATURE REPORTS: We also maintain a list with electronic links to PubMed for literature searches on all of our listed drugs. Each link triggers a search for the drug name and torsades/QT prolongation within the MeSH terminology/ keywords so that a comprehensive list of references to current medical literature can be conveniently accessed.
Drugs on the QT Drug Lists are reviewed on an ongoing basis to assure that the available evidence supports their continued placement on their respective list. Decisions regarding the placement of drugs on our lists is made in consultation with our QT Drugs Advisory Board.The most recent modification to the lists was made on 05/07/2013.